Work

P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Year: 2018

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.08.637

Authors: G. Riely, R. Hui, D. Carbone, K. Park, M. Carrigan, X. Xu, T. Dang, J. Chih-Hsin Yang

Institutions: Memorial Sloan Kettering Cancer Center, The University of Sydney, Westmead Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Samsung Medical Center, Sungkyunkwan University, Merck & Co., Inc., Rahway, NJ, USA (United States), National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2898134591

FWCI: 1.714

Cites:

Cited by: 22

Related to: 10